Luhan Pharmachem Co., Ltd.
FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatm 04-09
FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs The U S 12-14
FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient 12-14
New drug Vitrakvi targets specific receptor kinase that promotes tumors11-28
The U S Food and Drug Administration today approved ID COREXT, a molecular-based assay used in blood transfusion 10-17
Agency is taking additional steps to advance the development of new FDA-approved treatments for opioid dependence and encourage their more widespread use09-10
The U S Food and Drug Administration todayapproved the first drug, Oxervate (cenegermin), for the treatment ofneur 08-24
On August 16, 2018, the Food and Drug Administration approved lenvatinibcapsules (Lenvima, Eisai Inc ) for first-li 08-20
The U S Food and Drug Administration today approved the first genericversion of EpiPen and EpiPen Jr (epinephrine 08-17
FDAapproves treatment for two rare types of non-Hodgkin lymphomaThe U S Food and Drug Administration today approve 08-10
FDAapproves first generic drug under new pathway aimed at enhancing marketcompetition for sole source drugsThe U S 08-10
The European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended gran...07-30
Tel: +86 0871 6511 0906 (GMT+8 AM9:00-AM:12:00 PM1:30-PM6:00)
cell phone:188 1221 6310
Fax:0871-63602606
Email: info@luhancn.com
Address:Room 3301,33rd Floor Building B, Vogue Garden Plaza, No.1004 Beijing Road, Kunming, Yunnan Province, P. R. China 650000